Combining Azenosertib with Antibody-Drug Conjugates Demonstrates Synergistic Antitumor Effects
Time: 2:20 pm
day: Day One
Details:
- Exploring the synergistic antitumor effects of combining azenosertib with TOP1 inhibitors or ADCs with TOP1 inhibitor/microtubule inhibitor payloads in various cancer models
- Discussing the enhanced therapeutic efficacy observed when azenosertib is combined with trastuzumab deruxtecan (T-Dxd) in HER2+ breast cancer models, analyzing the potential to improve responses to TOP1 inhibitor-based ADCs in HER2+ ovarian and HER2-low breast cancer models, highlighting its broader implications for treating advanced solid tumors
- Discussing the potential for azenosertib as a general enhancer for ADCs with TOP1 inhibitor or microtubule inhibitor payloads
